SG11202001111QA - Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis - Google Patents
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosisInfo
- Publication number
- SG11202001111QA SG11202001111QA SG11202001111QA SG11202001111QA SG11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA
- Authority
- SG
- Singapore
- Prior art keywords
- alcoholic
- invasive diagnostic
- fatty liver
- liver fibrosis
- liver diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306201 | 2017-09-18 | ||
PCT/EP2018/074975 WO2019053233A1 (en) | 2017-09-18 | 2018-09-14 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001111QA true SG11202001111QA (en) | 2020-03-30 |
Family
ID=60001810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001111QA SG11202001111QA (en) | 2017-09-18 | 2018-09-14 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
Country Status (14)
Country | Link |
---|---|
US (1) | US11519034B2 (en) |
EP (1) | EP3684954A1 (en) |
JP (1) | JP7424981B2 (en) |
KR (1) | KR20200051676A (en) |
CN (1) | CN111065748B (en) |
AU (1) | AU2018332318A1 (en) |
BR (1) | BR112020004439A2 (en) |
CA (1) | CA3071219A1 (en) |
EA (1) | EA202090715A1 (en) |
IL (1) | IL272465A (en) |
MX (1) | MX2020002532A (en) |
PH (1) | PH12020500354A1 (en) |
SG (1) | SG11202001111QA (en) |
WO (1) | WO2019053233A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900005700A1 (en) * | 2019-04-12 | 2020-10-12 | Metadeq Ltd | NEW MARKER OF PATHOLOGY AND ITS USES |
CN114630660A (en) * | 2019-10-28 | 2022-06-14 | 基恩菲特公司 | Combination therapy with antioxidant properties |
CN111549123B (en) * | 2020-06-12 | 2022-10-21 | 中山大学附属第三医院 | Detection kit for circular RNA 0089762 and application thereof |
US20230296624A1 (en) * | 2020-08-03 | 2023-09-21 | Genfit | Method for nash risk assessment |
MX2023002308A (en) | 2020-08-25 | 2023-07-11 | Lilly Co Eli | Polymorphs of an ssao inhibitor. |
CN112712896B (en) * | 2021-03-26 | 2023-03-07 | 深圳市绘云生物科技有限公司 | Diagnosis device and computer system for detecting non-alcoholic fatty liver disease state of subject |
WO2024010753A1 (en) * | 2022-07-06 | 2024-01-11 | Georgetown University | Mirna biomarkers and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
ES2527438T3 (en) * | 2006-08-08 | 2015-01-26 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of their use |
FR2953220B1 (en) * | 2009-12-01 | 2012-11-23 | Oreal | MICROARN SIGNATURE OF EPIDERMIC DIFFERENTIATION AND USES |
US9221751B2 (en) * | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
WO2013166363A2 (en) * | 2012-05-03 | 2013-11-07 | The Johns Hopkins University | Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia |
WO2016196945A1 (en) * | 2015-06-05 | 2016-12-08 | Regulus Therapeutics Inc. | Non-alcoholic fatty liver disease biomarkers |
IL257680B2 (en) * | 2015-09-14 | 2023-03-01 | Genfit | Methods for diagnosing and evaluating non-alcoholic steatohepatitis |
-
2018
- 2018-09-14 BR BR112020004439-3A patent/BR112020004439A2/en unknown
- 2018-09-14 EA EA202090715A patent/EA202090715A1/en unknown
- 2018-09-14 AU AU2018332318A patent/AU2018332318A1/en active Pending
- 2018-09-14 CA CA3071219A patent/CA3071219A1/en active Pending
- 2018-09-14 SG SG11202001111QA patent/SG11202001111QA/en unknown
- 2018-09-14 MX MX2020002532A patent/MX2020002532A/en unknown
- 2018-09-14 JP JP2020537045A patent/JP7424981B2/en active Active
- 2018-09-14 EP EP18765677.2A patent/EP3684954A1/en active Pending
- 2018-09-14 CN CN201880058906.5A patent/CN111065748B/en active Active
- 2018-09-14 US US16/648,137 patent/US11519034B2/en active Active
- 2018-09-14 WO PCT/EP2018/074975 patent/WO2019053233A1/en unknown
- 2018-09-14 KR KR1020207009299A patent/KR20200051676A/en not_active Application Discontinuation
-
2020
- 2020-02-04 IL IL272465A patent/IL272465A/en unknown
- 2020-02-18 PH PH12020500354A patent/PH12020500354A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020004439A2 (en) | 2020-10-06 |
EP3684954A1 (en) | 2020-07-29 |
CN111065748A (en) | 2020-04-24 |
IL272465A (en) | 2020-03-31 |
JP7424981B2 (en) | 2024-01-30 |
EA202090715A1 (en) | 2020-07-15 |
WO2019053233A1 (en) | 2019-03-21 |
CA3071219A1 (en) | 2019-03-21 |
KR20200051676A (en) | 2020-05-13 |
PH12020500354A1 (en) | 2021-01-25 |
MX2020002532A (en) | 2020-07-20 |
US20200216901A1 (en) | 2020-07-09 |
CN111065748B (en) | 2024-04-09 |
JP2021502109A (en) | 2021-01-28 |
AU2018332318A1 (en) | 2020-02-20 |
US11519034B2 (en) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272869A (en) | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | |
IL272465A (en) | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | |
ZA201807083B (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
EP3454745A4 (en) | Diagnosis tailoring of health and disease | |
HK1249847A1 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
EP3426135A4 (en) | Non-invasive detection of skin disease | |
ZA201805634B (en) | Conjugate of therapeutic enzymes | |
EP3710831A4 (en) | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis | |
IL268502A (en) | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease | |
IL275188A (en) | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis | |
IL272937A (en) | Compositions and methods for the treatment of fibrotic diseases | |
EP3518918A4 (en) | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis | |
EP3781158A4 (en) | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | |
EP3362053A4 (en) | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine | |
HK1250205A1 (en) | Human milk compositions and methods of making and using same | |
IL271236A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
GB201710822D0 (en) | Methods and medical uses relating to the treatment of hypoglycaemia | |
EP3740592A4 (en) | Methods and compositions for the treatment of vascular disease | |
EP3459524A4 (en) | Human body cleaning agent and preparation method therefor | |
EP3679930A4 (en) | Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity | |
EP3716975A4 (en) | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis | |
EP3718552A4 (en) | Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis | |
EP3599984A4 (en) | Endoscopes and methods of use | |
EP3846843A4 (en) | Compositions and methods for the treatment of heart disease | |
EP3615003A4 (en) | Diagnosis and treatment of vitiligo |